Previous Article | Next Article 
Journal of Clinical Microbiology, April 1998, p. 1125-1127, Vol. 36, No. 4
Department of Microbiology, Akademisch
Ziekenhuis, Vrije Universiteit Brussel, 1090 Brussels,
Belgium,1 and
Department of Medical
Microbiology and Immunology, University of Alberta, Edmonton,
Alberta T6J 1Z9, Canada2
Received 4 August 1997/Returned for modification 10 October
1997/Accepted 23 December 1997
We produced a monoclonal antibody (MAb) to Ureaplasma
urealyticum Vancouver, the serotype 9 standard strain. By
immunoblotting, this MAb showed a single, 85-kDa band with the
homologous serotype and a minor, 100-kDa band with serotype 2 but did
not react with any other serotype standard strain. Clinical isolates of
U. urealyticum were tested with this MAb and with two
sets of polyclonal antisera against the 14 serotype standard strains.
The use of MAb 9-2H9 correctly identified certain serotype 9 strains
but did not react with wild-type strains lacking the serotype 9 determinant.
The establishment of
Ureaplasma urealyticum as a member of the normal genital
flora has made its role in genitourinary tract disease difficult to
define. Human inoculation studies finally demonstrated the
pathogenicity of this organism in some cases of nongonococcal
urethritis in males (22). The results of certain prospective
studies (2, 3, 8, 11) and case reports (1, 7)
have suggested a role for U. urealyticum in some infections of the female genital tract. The fact that many pregnant women are colonized with ureaplasmas but that few of these infections are associated with adverse effects has raised the possibility of
differential host susceptibility or strain pathogenicity. U. urealyticum strains comprise two biovars. The parvo biovar is comprised of serotypes 1, 3, 6, and 14, and the T960 biovar is comprised of serotypes 2, 4, 5, 7, 8, 9, 10, 11, 12, and 13 (17). An association between serotype and/or biovar and
pathogenicity has been hypothesized. Reliable means of determining the
biovar can be achieved by PCR (18), but the division of the
biovars by serotyping is beset with problems (21). Some of
the relatively few reports have indicated an association between
particular serotypes and disease (12, 19), while
others have not (9, 13, 16). Current methodologies
rely upon nonstandardized reagents, i.e., polyclonal antibodies
(PAbs) to whole-cell antigens. The expression of multiple
specificities by a single, purified strain of U. urealyticum (12, 21) confounds the interpretation of
the data. Serotyping with monoclonal antibodies (MAbs) to
serotype-specific antigens could reduce this problem. MAbs also could
be used to identify the location of these determinants and to assist in
their further characterization (4, 5, 24, 26).
Antigenic diversity has been identified among isolates of
U. urealyticum in vitro for serotypes 4 (4)
and 3 (5, 24) and in vivo for serotype 3 (25) and
may be essential for understanding pathogenicity. For example, specific
determinants might allow a strain to escape human immune responses or
to express a distinct property that promotes invasiveness.
Serotype-specific MAbs have been described for serotypes 1, 3, 4, 6, 8, and 10 (4, 5, 24). MAbs reacting with more than one serotype
have also been described. Cheng et al. described a MAb reacting with
serotypes 3 and 14 (5). Thirkell et al. (23)
described a MAb which reacts with all 14 serotypes and also, based on
immunoblotting patterns, distinguishes the two seroclusters or biovars.
Other MAbs have been described by Watson et al. (24);
one reacted with all 14 serotypes, while another reacted with all
serotypes except types 2 and 5.
We prepared MAbs against the U. urealyticum serotype 9 standard strain (strain Vancouver, progenitor of ATCC 33175) (6, 14), for which no serotype-specific antigens had been defined. MAbs were produced as previously described (4).
Briefly, BALB/c mice were injected intraperitoneally every 2 weeks with 0.5 ml of antigen (washed whole cells, containing
approximately 109 color-changing units ml We note that the serotype 9 standard antigen used as the immunogen was
from the same initial source as that used for preparing PAb-C (a set of
PAbs produced in Canada) and PAb-B (a set of PAbs produced in Brussels,
Belgium). After immunization with U. urealyticum serotype 9, one reactive clone, MAb 9-2H9, was identified by colony epifluorescence; it reacted with >90% of the colonies of the serotype 9 standard but not with the remaining 13 serotypes. When immunoblotting was performed (Fig. 1), MAb 9-2H9 reacted
strongly with a single band of ~85 kDa with the serotype 9 standard
strain but also weakly with a single band of ~100 kDa with the
serotype 2 standard strain. It did not react with the other 12 standard
strains. Thus, although this MAb was not completely specific for type
9, it should be useful for serotyping by colony epifluorescence.
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Development of a Monoclonal Antibody to a Ureaplasma
urealyticum Serotype 9 Antigen
ABSTRACT
Top
Abstract
Text
References
TEXT
Top
Abstract
Text
References
1 of
U. urealyticum serotype 9 reference strain). Freund's
complete adjuvant was added to the first injection; a final booster
dose of 0.2 ml of the same antigen preparation was given through
tail vein injection 3 days before fusion. Fusion was performed with spleen cells from immunized mice and nonsecreting P3-X63-Ag 8.653 mouse myeloma cells. The hybridoma clones were screened for the production of antibodies by colony epifluorescence (10),
with the serotype 9 reference strain used as the antigen.
View larger version (53K):
[in a new window]
FIG. 1.
Immunoblot showing the reaction pattern of MAb 9-2H9
(immunoglobulin G2a, specific to serotypes 2 and 9). Lanes 1 to 14 contain whole-cell preparations of the 14 serotype standard strains of
U. urealyticum. Molecular masses of the bands, in
kilodaltons, are indicated to the left of the gel.
MAb 9-2H9 was evaluated with seven clinical isolates. Earlier, in colony epifluorescence tests (20), these isolates had demonstrated reactivity with a serotype 9 polyclonal antiserum (16, 18) from PAb-C, the antiserum set prepared in Canada (15). The seven strains were now retested with PAb-B, the set of polyclonal antisera prepared in Belgium (12), and also with MAb 9-2H9 and MAbs to serotypes 1, 3, 4, 6, 7, and 14. DNA from these strains also was tested by 16S rRNA-based, biovar-specific PCRs (18). All results are shown in Table 1.
|
Of the seven isolates that the PAb-C reagent had recognized as bearing the serotype 9 determinant (as a single specificity or as one of multiple specificities), only four were recognized by PAb-B. The discrepancy between the two anti-serotype 9 antisera could reflect differences in the protocols used for the cultivation and preparation of the immunogen, immunization, or testing. Antibodies to the same antigen could be directed against different epitopes and thus elicit different test results. Only one study has examined the reproducibility of serotyping clinical isolates of U. urealyticum with polyclonal antisera (21), and it was limited to a single laboratory using a single set of reagents. Reproducibility of each serotype specificity ranged from 100 down to 67%, with an overall agreement of 87%. The interpretation of data obtained by using such reagents can confuse rather than clarify the objective of the research, which in this instance was the role of strain variation in disease. The present study is the first to compare U. urealyticum serotyping results obtained by two laboratories using nonidentical immunoreagents.
Although clinical isolates commonly show polyreactivity with polyclonal antisera (21), polyreactivity clearly reduces the utility of serotyping (21). In epifluorescence tests with either the 13 heterologous serotype standard strains or with 28 sequential isolates (17 of which had been thrice subcloned by limiting dilutions [15] to ensure purity), the partial set of MAbs available to us did not exhibit any polyreactivity (Table 1).
The four strains that reacted with the serotype 9 reagent of both PAb-C and PAb-B also reacted with MAb 9-2H9. The other three strains that reacted with only PAb-C anti-serotype 9 antiserum demonstrated other specificities for which MAbs were not available (Table 1).
When clinical isolates have been typed in Canada or in Belgium, with the full set of 14 specificities, the incidence of serotype 3 has predominated and the incidence of serotype 9 has been in the range of <1 to 15% (12, 16).
In conclusion, we have prepared a MAb to the serotype 9 determinant of U. urealyticum. Although this MAb is heterospecific by immunoblotting, it appears to have utility as a reagent for serotyping by colony epifluorescence.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology, Akademisch Ziekenhuis, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium. Phone: 32-02-4775000. Fax: 32-02-4775015. E-mail: labomicro{at}az.vub.ac.be.
Present address: Dept. of Veterinary and Biomedical Science,
University of Nebraska
Lincoln, Lincoln, NE 68583-0905.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. | Cassell, G. H., R. O. Davis, K. B. Waites, M. B. Brown, P. A. Marriot, S. Stagno, and J. K. Davis. 1983. Isolation of Mycoplasma hominis and Ureaplasma urealyticum from amniotic fluid at 16-20 weeks of gestation: potential effect on outcome of pregnancy. Sex. Transm. Dis. 10:294-302[Medline]. |
| 2. | Cassell, G. H., K. B. Waites, D. Crouse, P. T. Rudd, K. C. Canupp, S. Stagno, and G. R. Cutter. 1988. Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very low birth weight infants. Lancet ii:240-244. |
| 3. |
Cassell, G. H.,
K. B. Waites,
H. L. Watson,
D. T. Crouse, and R. Harasawa.
1993.
Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newborns.
Clin. Microbiol. Rev.
6:69-87 |
| 4. |
Cheng, X.,
A. Naessens, and S. Lauwers.
1993.
Identification and characterization of serotype 4-specific antigens of Ureaplasma urealyticum by use of monoclonal antibodies.
Infect. Immun.
61:2253-2256 |
| 5. |
Cheng, X.,
A. Naessens, and S. Lauwers.
1994.
Identification of serotypes 1-, 3- and 6-specific antigens of Ureaplasma urealyticum by monoclonal antibodies.
J. Clin. Microbiol.
32:1060-1062 |
| 6. | Ford, D. K., and J. R. Smith. 1974. Non-specific urethritis associated with a tetracycline-resistant T-mycoplasma. Br. J. Vener. Dis. 50:373-374[Medline]. |
| 7. | Foulon, W., A. Naessens, M. Dewaele, S. Lauwers, and J. J. Amy. 1986. Chronic Ureaplasma urealyticum amnionitis associated with abruptio placentae. Obstet. Gynecol. 68:280-283[Medline]. |
| 8. | Foulon, W., D. Van Liedekerke, C. Demanet, L. Decatte, M. Dewaele, and A. Naessens. 1995. Markers of infection and their relationship to preterm delivery. Am. J. Perinatol. 12:208-211[Medline]. |
| 9. | Hewish, M. J., D. F. Buch, and K. F. Fairley. 1986. Ureaplasma urealyticum serotypes in urinary tract disease. J. Clin. Microbiol. 23:145-154. |
| 10. |
Naessens, A., and S. Lauwers.
1987.
Modified indirect immuno-fluorescence test for serotyping large numbers of Ureaplasma urealyticum clinical isolates.
J. Clin. Microbiol.
25:191-192 |
| 11. | Naessens, A., W. Foulon, H. Cammu, A. Goossens, and S. Lauwers. 1987. Epidemiology and pathogenesis of Ureaplasma urealyticum in pregnancy and early preterm labor. Scand. J. Obstet. Gynecol. 66:513-516. |
| 12. |
Naessens, A.,
W. Foulon,
J. Breynaert, and S. Lauwers.
1988.
Serotypes of Ureaplasma urealyticum isolated from normal pregnant women and patients with pregnancy complications.
J. Clin. Microbiol.
26:319-322 |
| 13. | Piot, P. 1976. Distribution of eight serotypes of Ureaplasma urealyticum in cases of non-gonococcal urethritis and of gonorrhoea, and in healthy persons. Br. J. Vener. Dis. 52:266-268[Medline]. |
| 14. |
Robertson, J. A., and G. W. Stemke.
1979.
Modified metabolic inhibition test for serotyping strains of Ureaplasma urealyticum (T-strain mycoplasma).
J. Clin. Microbiol.
9:673-676 |
| 15. |
Robertson, J. A., and G. W. Stemke.
1982.
Expanded serotyping scheme for Ureaplasma urealyticum strains isolated from humans.
J. Clin. Microbiol.
15:873-878 |
| 16. | Robertson, J. A., L. H. Honore, and G. W. Stemke. 1986. Serotypes of Ureaplasma urealyticum in spontaneous abortion. Pediatr. Infect. Dis. 5:S270-S272[Medline]. |
| 17. |
Robertson, J. A.,
L. E. Pyle,
G. W. Stemke, and L. R. Finch.
1990.
Human ureaplasmas show diverse genome sizes by pulsed-field electrophoresis.
Nucleic Acids Res.
18:1451-1455 |
| 18. |
Robertson, J. A.,
A. Vékris,
C. Bébéar, and G. W. Stemke.
1993.
PCR based upon 16S ribosomal RNA gene sequences distinguishes the two biovars of Ureaplasma urealyticum.
J. Clin. Microbiol.
31:824-830 |
| 19. |
Shepard, M. C., and C. D. Lunceford.
1978.
Serological typing of Ureaplasma urealyticum isolates from urethritis patients by an agar growth inhibition method.
J. Clin. Microbiol.
8:566-574 |
| 20. |
Stemke, G. W., and J. A. Robertson.
1981.
Modified colony indirect epifluorescence test for serotyping Ureaplasma urealyticum and an adaptation to detect common antigenic specificity.
J. Clin. Microbiol.
14:582-584 |
| 21. | Stemke, G. W., and J. A. Robertson. 1985. Problems associated with serotyping strains of Ureaplasma urealyticum. Diagn. Microbiol. Infect. Dis. 3:311-320[Medline]. |
| 22. |
Taylor-Robinson, D.,
G. W. Csonka, and M. J. Prentice.
1977.
Human intra-urethral inoculation of ureaplasmas.
Q. J. Med.
46:309-326 |
| 23. |
Thirkell, D.,
A. D. Myles, and W. C. Russell.
1989.
Serotype 8- and serocluster-specific surface-expressed antigens of Ureaplasma urealyticum.
Infect. Immun.
57:1697-1701 |
| 24. |
Watson, H. L.,
D. K. Blalock, and G. H. Cassell.
1990.
Variable antigens of Ureaplasma urealyticum containing both serotype-specific and serotype-cross-reactive epitopes.
Infect. Immun.
58:3679-3688 |
| 25. |
Zheng, X.,
H. L. Watson,
K. B. Waites, and G. H. Cassell.
1992.
Serotype diversity and antigen variation among invasive isolates of Ureaplasma urealyticum from neonates.
Infect. Immun.
60:3472-3474 |
| 26. | Zheng, X., L. J. Teng, H. L. Watson, J. I. Glass, A. Blanchard, and G. H. Cassell. 1995. Small repeating units within the Ureaplasma urealyticum MB antigen gene encode serovar specificity and are associated with antigen size variation. Infect. Immun. 63:891-898[Abstract]. |
Journal of Clinical Microbiology, April 1998, p. 1125-1127, Vol. 36, No. 4
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Vancutsem, E., Echahidi, F., Van Geel, K., Muyldermans, G., Soetens, O., Naessens, A.
(2008). Production of Recombinant Antigens of Ureaplasma parvum Serotypes 3 and 6 for Development of a Serological Assay. CVI
15: 447-451
[Abstract] [Full Text] -
Echahidi, F., Muyldermans, G., Lauwers, S., Naessens, A.
(2001). Development of an Enzyme-Linked Immunosorbent Assay for Serotyping Ureaplasma urealyticum Strains Using Monoclonal Antibodies. CVI
8: 52-57
[Abstract] [Full Text] -
Echahidi, F., Muyldermans, G., Lauwers, S., Naessens, A.
(2000). Development of Monoclonal Antibodies against Ureaplasma urealyticum Serotypes and Their Use for Serotyping Clinical Isolates. CVI
7: 563-567
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»